Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN4461 (mibavademab) in familial partial lipodystrophy
NCT05088460Phase 2Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Feb 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of mibavademab in familial partial lipodystrophy (FPLD), sponsored by Regeneron Pharmaceuticals. Started Feb 2022; status: terminated.
02
Drugs
mibavademab
03
Conditions
familial partial lipodystrophy (FPLD)
Beyond the preview
Go deeper on NCT05088460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05088460.